A Phase II Open Label Study of the Safety, Pharmacokinetics, and Efficacy of a True Human Anti-inflammatory Therapeutic Antibody (RA-18C3) in Subjects With Moderate to Severe Plaque Psoriasis.
Phase of Trial: Phase II
Latest Information Update: 04 Mar 2015
At a glance
- Drugs MABp1 (Primary)
- Indications Plaque psoriasis
- Focus Adverse reactions
- 10 Jun 2017 Biomarkers information updated
- 04 Mar 2015 According to a XBiotech media release, results from this study have been published in the JAMA Dermatology.
- 04 Mar 2015 Results published in a XBiotech media release.